Treatment of acute uncomplicated influenza in patients who have had symptoms for 2 days or less.
Inhibits the enzyme neuraminidase, which may alter virus particle aggregation and release.
Reduced duration or prevention of flu-related symptoms.
Absorption: IV administration results in complete bioavailability.
Metabolism and Excretion: Mostly eliminated unchanged by kidneys (> 90%).
Half-life: 20.8 hr.
TIME/ACTION PROFILE (blood levels)
|IV||rapid||end of infusion||unknown|
Use Cautiously in:
CNS: insomnia, neuropsychiatric events
Derm: ERYTHEMA MULTIFORME, STEVENS-JOHNSON SYNDROME
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Avoid use of live attenuated influenza vaccine within 2 wk prior and 48 hr after peramivir; interference may occur.
IV:(Adults and Children≥13 yr): 600 mg x 1 dose.
IV:(Children2–12 yr): 12 mg/kg (max = 600 mg) x 1 dose.
IV:(Adults and Children≥13 yr): CCr 30–49 mL/min–200 mg x 1 dose; CCr 10–29 mL/min–100 mg x 1 dose.
IV:(Children2–12 yr): CCr 30–49 mL/min–4 mg/kg (max = 600 mg) x 1 dose; CCr 10–29 mL/min–2 mg/kg (max = 600 mg) x 1 dose.
Solution for injection: 10 mg/mL
Lab Test Considerations:
May cause ↑ serum ALT, AST, glucose, creatine kinase, and ↓ neutrophils.
Resolution of sign and symptoms of influenza.
Davis’s Drug Guide for Nurses App + Web from F.A. Davis and Unbound Medicine covers 5000+ trade name and generic drugs. Includes App for iPhone, iPad, and Android smartphone + tablet. Handbook covers dosage, side effects, interactions, uses. Davis Drug Guide PDF. Complete Product Information.